PRMT5 and acute myeloid leukemia: Tumor intrinsic alteration of splicing through the frequently seen mutation in RNA splicing factors (SRSF2, SF3B1 and U2AF1) in AML cells confers vulnerability to either PRMT1 inhibition (MS023, [73]), PRMT5 inhibition (GSK3203591, [74]), or both [14].